Abstract: Cabotegravir (GSK1265744) is a potent human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) developed for both the treatment and prevention of HIV-1 infection. To address the clinical challenges of daily oral antiretroviral adherence, cabotegravir has been formulated as a novel long-acting (LA) injectable nanosuspension. This advanced drug delivery system exhibits unique pharmacokinetic properties, characterized by dissolution-controlled absorption from an intramuscular depot and a significantly prolonged apparent half-life, enabling monthly or bimonthly administration. When co-administered with long-acting rilpivirine, it provides a complete, fully injectable regimen for maintaining virologic suppression. Furthermore, cabotegravir LA has demonstrated high efficacy as a single agent for HIV pre-exposure prophylaxis (PrEP). This review explores the pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations—such as injection site reactions and the prolonged pharmacokinetic "tail"—and future perspectives of cabotegravir in the landscape of HIV management.
1. Introduction
The advent of combination antiretroviral therapy (cART) has transformed HIV-1 infection into a manageable chronic disease, significantly reducing HIV-related morbidity and mortality [2][3]. However, the long-term success of cART relies heavily on strict adherence to daily oral regimens. Suboptimal adherence can lead to insufficient drug exposure, virologic failure, and the emergence of drug-resistant viral strains [3][4]. To overcome adherence barriers such as pill fatigue, stigma, and privacy concerns, long-acting (LA) injectable antiretrovirals have emerged as a paradigm-shifting approach in HIV care [9].
Cabotegravir (GSK1265744) is a novel INSTI that possesses intrinsic physicochemical properties—such as high antiviral potency, low aqueous solubility, and a long systemic half-life—making it an ideal candidate for formulation as a sterile, injectable nanosuspension [1][2]. Cabotegravir LA, in combination with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine LA, has been approved as the first complete long-acting injectable regimen for HIV-1 maintenance therapy [9]. Additionally, cabotegravir LA is being extensively evaluated and utilized as a highly effective single agent for HIV pre-exposure prophylaxis (PrEP) [7].
2. Pharmacological Activity
Formulation and Absorption: Cabotegravir LA is formulated as a 200 mg/mL sterile aqueous nanosuspension containing crystalline nano-sized particles (average size of approximately 200 nm) manufactured via a wet-bead milling process [1]. It acts as a dissolution-controlled depot; the rate-limiting step for drug absorption is the dissolution of the nanoparticles into the interstitial fluid surrounding the injection site [1]. This mechanism results in "flip-flop" pharmacokinetics, where the apparent terminal half-life is dictated by the slow absorption rate from the tissue depot rather than systemic elimination [1][3]. Following intramuscular (IM) injection, the apparent half-life ranges from 21 to 54 days (or 5.6 to 11.5 weeks), a stark contrast to the approximately 40-hour half-life of the oral formulation [1][4].
Distribution: Cabotegravir is highly protein-bound (>99.8%) in plasma, primarily to albumin [4][6]. Tissue distribution studies indicate that cabotegravir penetrates the female genital tract (vaginal and cervical tissues) at median tissue-to-plasma ratios of 16% to 28%, and rectal tissue at approximately 8% [1][2]. Despite this relatively low mucosal penetration compared to plasma, these concentrations are sufficient to provide robust protection against HIV acquisition in PrEP models [1].
Metabolism and Excretion: Cabotegravir is primarily metabolized in the liver by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with a minor contribution from UGT1A9 [1][4]. It is eliminated mainly in the feces (58.5% mean recovery) as unchanged drug, likely due to biliary excretion and enterohepatic recirculation, while a smaller proportion (26.8%) is excreted in the urine exclusively as a glucuronide metabolite [1]. Cabotegravir does not significantly induce or inhibit cytochrome P450 (CYP) enzymes, resulting in a low propensity for drug-drug interactions, though it remains susceptible to interactions with strong UGT inducers [1][4].
3. Molecular Mechanism of Action
Cabotegravir exerts its potent antiviral activity by targeting the HIV-1 integrase enzyme. Specifically, it binds to the active site of the integrase enzyme and blocks the strand transfer step of viral complementary DNA (cDNA) integration into the host cell genome [2][4]. By preventing the virus from establishing a proviral state, cabotegravir effectively halts the viral replication cycle. In vitro, cabotegravir demonstrates subnanomolar potency, with a half-maximal inhibitory concentration (IC50) of 0.22 to 0.34 nmol/L against wild-type HIV-1 strains in peripheral blood mononuclear cells [2][3]. The protein-adjusted 90% inhibitory concentration (PA-IC90) is estimated at 166 ng/mL, which serves as a critical pharmacokinetic target for maintaining therapeutic efficacy [1][2].
4. Structure-Activity Relationship (SAR)
Cabotegravir is a carbamoyl pyridone analogue and shares a close structural relationship with the next-generation INSTI dolutegravir, differing by only one carbon atom [5][7]. Its chemical structure was specifically optimized to enable long-acting, infrequent dosing while maintaining a high genetic barrier to resistance [7]. Unlike earlier antiretrovirals where a single point mutation could confer high-level resistance, cabotegravir generally requires multiple coding mutations to significantly reduce its potency. In vitro studies and clinical isolate testing have identified that combinations of mutations at integrase positions 74, 97, 138, 140, 147, 148, 155, and 263 are necessary to confer moderate (>10-fold) to high-level (>100-fold) resistance. For instance, the highest level of resistance (>1000-fold) is observed with the mutation combination T97A/G140S/G148H, with or without E138A [7].
5. Current Limitations
Despite its clinical advantages, cabotegravir LA faces several pharmacological and practical limitations:
The Pharmacokinetic "Tail": Following the cessation of IM injections, cabotegravir exhibits a prolonged pharmacokinetic tail, remaining detectable in plasma for up to 52 weeks, and in some cases, up to 228 weeks [7][8]. During this tail phase, sub-therapeutic drug concentrations persist, posing a significant risk for the selection of INSTI-resistant HIV strains if the patient is exposed to the virus or experiences virologic rebound [4][7].
Injection Site Reactions (ISRs): The most common adverse events associated with cabotegravir LA are ISRs, including pain, erythema, and nodule formation at the gluteal injection site. Although mostly mild to moderate and transient, these reactions can affect patient acceptability and adherence [1][3].
Pharmacokinetic Variability: There is wide inter-individual variability in the absorption rate of cabotegravir LA. Factors such as sex and body mass index (BMI) influence its pharmacokinetics; for example, lower BMI is associated with faster absorption, while higher BMI and female sex are associated with a longer apparent terminal half-life [1][7].
Pregnancy and Special Populations: There is a lack of comprehensive data regarding the pharmacokinetics and safety of cabotegravir LA during pregnancy. Physiological changes during pregnancy, such as increased UGT1A1 activity and altered protein binding, could potentially increase drug clearance and reduce exposure, necessitating further prospective evaluation [6][7].
6. Future Perspectives
The successful development of cabotegravir LA paves the way for a new paradigm in HIV management. Ongoing and future clinical trials (such as the open-label extensions of HPTN 083 and 084, ATLAS-2M, and FLAIR) continue to evaluate the long-term safety, efficacy, and optimal dosing intervals (e.g., every 8 weeks versus every 4 weeks) of cabotegravir LA [4][7]. A critical area of future research involves developing strategies to safely manage the pharmacokinetic tail, such as transitioning patients to oral PrEP or alternative suppressive oral cART upon discontinuation of the injectable [7][9]. Furthermore, expanding the use of cabotegravir LA to diverse populations, including adolescents and pregnant individuals, will be essential [7][9]. Advances in physiologically based pharmacokinetic (PBPK) modeling will also aid in predicting drug-drug interactions, understanding intestinal metabolism, and optimizing dosing regimens in special populations [4][5].
